SynthesisSleep & breathing = Schlaf & Atmung2026
Impact of continuous positive airway pressure therapy on renin-angiotensin-aldosterone system in obstructive sleep apnea: an updated systematic review and meta-analysis.
Synthesis in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeWhile continuous positive airway pressure (CPAP) reduces cardiovascular risk in obstructive sleep apnea (OSA), its effects on renin–angiotensin–aldosterone system (RAAS) modulation remain controversial. This meta-analysis investigates CPAP's differential impacts on RAAS components and identifies responsive patient subgroups.
methodsSixteen studies were included in the systematic review and eight (231 patients) in the meta-analysis. Primary outcomes included plasma aldosterone concentration (PAC), plasma renin activity (PRA), and angiotensin II (AngII) changes. Subgroup analyses examined age, BMI, and CPAP duration thresholds, with meta-regression assessing moderating factors.
resultsCPAP significantly reduced PAC (d + of -0.72, 95% CI -1.39 to -0.05, p = 0.036), though statistical significance was attenuated in adjusted models, and improved daytime hemodynamics: systolic BP (d + -0.81), diastolic BP (d + -1.30), and heart rate (d + -1.61). Notably, patients < 50 years showed marked PAC reduction (d + -1.12, 95% CI -1.88 to -0.35), as did those with CPAP adherence ≥ 3 months (d + -0.88, 95% CI -1.86 to 0.09). No significant changes occurred in PRA (p = 0.917), plasma renin concentration (p = 0.463), or AngII (p = 0.058) in the overall cohort. Meta-regression revealed no significant associations between age, BMI, or CPAP duration and RAAS changes (all p > 0.05).
conclusionCPAP demonstrates selective RAAS modulation – significantly lowering PAC – alongside pronounced hemodynamic benefits, even though overall renin and AngII levels did not change significantly. Younger patients (< 50 years) and those maintaining ≥ 3 months therapy show aldosterone responsiveness, suggesting duration-dependent physiological effects. These findings highlight CPAP's potential role in targeted RAAS modulation and underscore the need for personalized treatment strategies in OSA management.
Indexed as
Identifiers
42043458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.